[Federal Register Volume 67, Number 18 (Monday, January 28, 2002)]
[Notices]
[Pages 3904-3905]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-2030]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with

[[Page 3905]]

35 U.S.C. 207 to achieve expeditious commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

HGC-1, A Gene Encoding a Member of the Olfactomedin-Related Protein 
Family

Griffin P. Rodgers, Wen-Li Liu, Jiachang Zhang (NIDDK)

DHHS Reference No. E-166-01/0 filed 07 Dec 2001
Licensing Contact: Kai Chen; 301/496-7736 ext. 247; e-mail: 
[email protected]
    The current technology embodies a newly identified gene, Human 
Granulocyte Colony-Stimulating Factor-Stimulated-Clone-1 (hGC-1), that 
has been cloned and characterized, and its protein sequence has been 
deduced. The gene is expressed in the bone marrow, prostate, small 
intestine, colon, and stomach, and has been mapped to chromosome 13 in 
a region that contains a tumor suppressor gene cluster. The gene is 
found to be selectively present in normal human myeloid lineage cells 
and is believed to play a role in allowing lymphocytes to differentiate 
properly. It is believed that the gene may be used as a selective 
marker for human prostate cancer, multiple myeloma, B-cell chronic 
lymphocytic leukemia and other types of cancer and can be used 
diagnostically as well as in therapeutic screening activities.

Mitochondrial Topoisomerase I

Yves Pommier and Hong-Liang Zhang (NCI)

DHHS Reference No. E-099-01/0 filed 16 Feb 2001
Licensing Contact: Matthew Kiser; 301/496-7056 ext. 224; e-mail: 
[email protected]
    The subject technology is an isolated or purified nucleic acid 
molecule consisting essentially of a nucleotide sequence encoding 
mitochondrial topoisomerase I (top1mt), a variant top1mt, or a fragment 
of either of the foregoing, an isolated or purified nucleic acid 
molecule consisting essentially of a nucleotide sequence that is 
complementary to a nucleotide sequence encoding top1mt, a variant 
top1mt, or a fragment of either of the foregoing, a vector comprising 
such an isolated or purified nucleic acid molecule, a cell comprising 
such a vector, an isolated or purified polypeptide molecule consisting 
essentially of an amino acid sequence encoding top1mt or a variant 
top1mt, a conjugate comprising such an isolated or purified polypeptide 
molecule and a cell-surface targeting moiety, a hybridoma cell line 
that produces a monoclonal antibody that is specific for an 
aforementioned isolated or purified polypeptide molecule, the 
monoclonal antibody produced by the hybridoma cell line, a polyclonal 
antiserum raised against an aforementioned isolated or purified 
polypeptide molecule, a method of altering the level of top1mt in a 
cell, and a method of identifying an inhibitor or an activator of top 1 
mt.

    Dated: January 17, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 02-2030 Filed 1-25-02; 8:45 am]
BILLING CODE 4140-01-P